🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Birmingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Birmingham

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Janssen Research & Development, LLC17 Merck Sharp & Dohme LLC16 Bristol-Myers Squibb14 Eli Lilly and Company14
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
470 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518Ventricular Tachycardia
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
NCT04489225Heart Failure
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Genentech, Inc.
Phase 1
498
Birmingham, Cardiff, London, Manchester
2020-07-29
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Sarepta Therapeutics, Inc.
Phase 3
160
Leeds, Birmingham, London
2020-07-13
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511Alzheimer Disease
Eli Lilly and Company
Phase 3
1,736
Motherwell, London, Guildford, Birmingham
2020-06-19
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
NCT04404660Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Turning Point Therapeutics, Inc.
Phase 1/2
75
Liverpool, Birmingham, Cardiff, Glasgow, London
2020-03-12
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds
2020-01-16
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
Laminar Pharmaceuticals
Phase 2/3
144
Newcastle, Birmingham, Cambridge, London
2019-12-01
Active, closed
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
655
Bellshill, London, Londonderry, Hexham, Birmingham, Cardiff, Manchester
2019-11-26
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Hoffmann-La Roche
Phase 1/2
170
Birmingham, Manchester
2019-11-11
Recruiting
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
NCT04006808Herpes Zoster
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT04083781Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Novo Nordisk A/S
Phase 3
134
Birmingham, London, Manchester, Nottingham, Sheffield
2019-10-21
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Recruiting
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
NCT04253015Neuroblastoma
RECORDATI GROUP
Observational
125
Newcastle upon Tyne, Birmingham, Southampton
2019-09-30
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
BeOne Medicines
Phase 3
510
Abergavenny, Birmingham, Dudley, Sutton
2019-08-20
Active, closed
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
75
Hampstead, Birmingham
2019-07-09
Active, closed
Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications.
NCT03570606Bone Deformity
Ceramisys Ltd
Observational
220
Doncaster, Birmingham, North Shields, Salford, Stoke-on-Trent, Taunton
2019-06-13
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429NASH - Nonalcoholic Steatohepatitis
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Birmingham, Cambridge, Chorley, Hardwick, Liverpool, London, Manchester, Newcastle upon Tyne
2019-03-28
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
Post-Authorization Long-Term Safety Study of LUTATHERA
NCT03691064Neuroendocrine Tumors
Advanced Accelerator Applications
Observational
1,014
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield
2018-11-28
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388Differentiated Thyroid Cancer
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
NCT03636438Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc
Observational
11
Birmingham
2018-08-30
Active, closed
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973Metastatic Urothelial Cancer
Gilead Sciences
Phase 2
502
Birmingham, London, Northwood, Surrey
2018-08-13
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
NCT03695978Haemophilia A
Octapharma
Observational
200
Headington, Birmingham, London, Newcastle upon Tyne
2018-02-13
Active, closed
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
Pierre Fabre Medicament
Phase 3
115
Birmingham, London
2017-12-29
Active, closed
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506Primary Biliary Cirrhosis
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness
2017-09-12
Active, closed
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414Tuberous Sclerosis Complex
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Active, closed
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943Heart Failure
Medtronic
Observational
1,092
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2017-08-21
Active, closed
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608Carcinoma, Non-Small-Cell Lung
Pfizer
Phase 3
296
Ipswich, Birmingham, Manchester
2017-04-27
Active, closed
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520HIV Infections
ViiV Healthcare
Phase 3
631
Birmingham, Coventry, Leeds Yorkshire, London
2016-10-27
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922Leukemia, Myeloid, Acute
Celgene
Phase 1/2
130
Birmingham, Headington, London, Sutton (Surrey)
2016-06-03
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Birmingham, London
2015-11-02
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Birmingham, Colchester, Essex, London
2015-10-31
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423Solid Tumors, Lymphoma
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
982
Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral
2014-11-26
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Cambridge, London, Manchester, Salford, Birmingham
2013-05-30
Active, closed
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity
Zimmer Biomet
Observational
255
Birmingham
2012-03
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Barnstaple, Birmingham, Blackpool, Bristol, Chelmsford, Glasgow, Harrow, Leeds
2012-01
Active, closed
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
NCT01081951Ovarian Cancer
AstraZeneca
Phase 2
162
Birmingham, Coventry, Edinburgh
2010-02-04
Recruiting
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
NCT00903110IGF1 Deficiency
Esteve Pharmaceuticals, S.A.
Observational
500
Belfast, Birmingham, Leeds, London, Manchester
2008-12-09
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne
2004-09-15
Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742Fabry Disease
Genzyme, a Sanofi Company
Observational
9,000
Cambridge, Birmingham, London, Salford, Belfast, Manchester
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Cambridge, Birmingham, London, Salford, Manchester
1991-04-01
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester
1983-01
Rows per page Showing 401–470 of 470
Previous 3 4 5
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk/city/birmingham?page=5

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.